

## Telaprevir und Boceprevir, zwei Proteaseinhibitoren des Hepatitis-C-Virus

## Télaprévir et bocéprévir, deux inhibiteurs de la protéase du virus de l'hépatite C

### Literatur / Références

- 1 Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. *J Hepatol.* 2011;55:192–206.
- 2 Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med.* 2011;364:2405-16.
- 3 Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med.* 2011;364:1195-206.
- 4 Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med.* 2011;365:1014-24.
- 5 Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. *N Engl J Med.* 2011;364:2417-28.
- 6 Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med.* 2011;364:1207-17.
- 7 Bronowicki JP, Davis M, Flamm S, Gordon S, Lawitz E, Yoshida E, et al. Sustained Virologic Response (SVR) in Prior PegInterferon/Ribavirin (PR) Treatment Failures After Retreatments with Boceprevir (BOC) + PR: PROVIDE Study Interim Results. *J Hepatol.* 2012;56(suppl 2):S6.
- 8 Swiss Association for the Study of the Liver. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. *Swiss Med Wkly.* 2012;142:w13516.
- 9 [www.hep-druginteractions.org](http://www.hep-druginteractions.org), accessed on March 13, 2013.
- 10 Cacoub P, Bourlière M, Lübke J, Dupin N, Buggisch P, Dusheiko G, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. *J Hepatol.* 2012;56:455-63.
- 11 Hezode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S, et al. Safety of telaprevir and boceprevir in combination with peginterferon alfa/ribavirin in cirrhotic non responders. First results of the French early access program (ANRS CO-20 CUPIC). *J Hepatol.* 2012;56(suppl 2):S4.
- 12 Dieterich DT, Soriano V, Sherman K, Girard P-M, Rockstroh J, et al. Telaprevir in combination with pegylated interferon- $\alpha$ -2a+RBV in HCV/HIV-co-infected patients: a 24-week treatment interim analysis. Conference on Retroviruses and Other Opportunistic Infections, Seattle, 2012, abstract #46.
- 13 Sulkowski MS, Pol S, Cooper C, Fainboim H, Slim J, et al. Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV-coinfected patients: end of treatment (week 48) interim results. Conference on Retroviruses and Other Opportunistic Infections, Seattle, 2012, abstract #47.